Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Jiawei Guo 1, * , Jing Lv 1, * , Siyu Chang 1 , Zhi Chen 1 , Weiqiang Lu 1 , Chuanliang Xu 2 , Mingyao Liu 1, 3 , Xiufeng Pang 1 1 Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China 2 Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China 3 Institute of Biosciences and Technology, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Houston, Texas 77030, USA * These authors contributed equally to this work Correspondence to: Xiufeng Pang, email: xfpang@bio.ecnu.edu.cn Keywords: RNA-binding protein, pyrvinium pamoate, DNA damage response, chemosensitivity, urothelial carcinoma of the bladder Received: February 16, 2016 Accepted: May 28, 2016 Published: June 09, 2016 ABSTRACT HuR, an RNA-binding protein, post-transcriptionally regulates nearly 4% of encoding proteins implicated in cell survival. Here we show that HuR is required for the efficacy of chemotherapies in urothelial carcinoma of the bladder. We identify pyrvinium pamoate, an FDA-approved anthelminthic drug, as a novel HuR inhibitor that dose-dependently inhibited cytoplasmic accumulation of HuR. Combining pyrvinium pamoate with chemotherapeutic agents (e.g. cisplatin, doxorubicin, vincristine and oxaliplatin) not only led to enhanced cytotoxicity in bladder cancer cells but also synergistically suppressed the growth of patient-derived bladder tumor xenografts in mice ( P < 0.001). Mechanistically, pyrvinium pamoate promoted nuclear import of HuR by activating the AMP-activated kinase/importin α1 cascade and blocked HuR nucleo-cytoplasmic translocation by inhibiting the checkpoint kinase1/cyclin-dependent kinase 1 pathway. Notably, pyrvinium pamoate-additive treatment increased DNA double-strand breaks as indicated by elevated γH2AX expression, suggesting an involvement of DNA damage response. We further found that pyrvinium pamoate dramatically downregulated several key DNA repair genes in genotoxically-stressed cells, including DNA ligase IV and BRCA2, leading to unbearable genomic instability and cell death. Collectively, our findings are the first to characterize a clinical HuR inhibitor and provide a novel therapeutically tractable strategy by targeting cytoplasmic translocation of HuR for treatment of urothelial carcinoma of the bladder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Brennan, C. M., & Steitz*, J. A. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000854 · Cited by 1,095 · cited 1×
“HuR, one of the best-studied RBPs implicated in DDR, is indispensable for the stabilization of short-lived mRNAs [13].”
BackgroundIniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615 · cited 1×
“DDR includes cell cycle arrest and DNA repair events where homologous recombination (HR) and non-homologous end joining (NHEJ) help cells to maintain genomic stability and escape from chemotherapy [7, 8].”
BackgroundTomitsuka, E., Kita, K., & Esumi, H. (2012) · The Journal of Biochemistry · doi:10.1093/jb/mvs041 · Cited by 79 · cited 1×
“Pyrvinium pamoate has been reported to suppress mitochondrial energy metabolism by inhibiting the NADH-fumarate reductase system [25].”
Background
Cited by
The novel role of pyrvinium in cancer therapy
Momtazi‐borojeni, A. A., Abdollahi, E., Ghasemi, F., Caraglia, M., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26006 · Cited by 75
“Pyrvinium was known to be a HuR inhibitor that can dose-dependently inhibit nucleo-cytoplasmic translocation of HuR through suppressing the checkpoint kinase1/cyclin dependent kinase 1 pathway (Table 1) (Guo et al., 2016).”
BackgroundInfluentialSchultz, C. W., McCarthy, G. A., Nerwal, T., Nevler, A., DuHadaway, J. B., McCoy, M. D., Jiang, W., Brown, S. Z., Goetz, A., Jain, A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0652 · Cited by 34
Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer
Feng, J., Jiang, W., Liu, Y., Huang, W., Hu, K., Li, K., Chen, J., Ma, C., Sun, Z., & Pang, X. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113960 · Cited by 23
Self-citationZheng, W., Hu, J., Lv, Y., Bai, B., Shan, L., Chen, K., Dai, S., & Zhu, H. (2021) · Medical Oncology · doi:10.1007/s12032-021-01472-3 · Cited by 21
Ponzini, F. M., Schultz, C. W., Leiby, B. E., Cannaday, S., Yeo, T., Posey, J., Bowne, W. B., Yeo, C., Brody, J. R., Lavu, H., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-073839 · Cited by 15
Metadata
- Authors
- Guo, J., Lv, J., Chang, S., Chen, Z., Lu, W., Xu, C., Liu, M., & Pang, X.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-06-09
- Volume
- 7
- Issue
- 29
- Pages
- 45249-45262
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2418255697
- Cited by
- 53
- References
- 5
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder. https://app.cochat.ai/papers/10.18632/oncotarget.9932
- The paper
- Guo, J., Lv, J., Chang, S., Chen, Z., Lu, W., Xu, C., Liu, M., & Pang, X. (2016). Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder. Oncotarget. https://doi.org/10.18632/oncotarget.9932
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.